🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the effort against superbug strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are increasing worldwide, with data suggesting over 82 million infections annually. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, also known as a brand name, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

According to findings published in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses two antibiotics. The study included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have expressed optimism. Having a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.